Megablock­buster day for Roche too as MS game-chang­er Ocre­vus gets a green light at the FDA

Sev­erin Schwan, Roche CEO

Tues­day turned out to be the day for a game of megablock­busters. Re­gen­eron and Sanofi snagged an FDA OK for Dupix­ent, a land­mark new eczema ther­a­py, and now Roche came through with a thumbs up for ocre­lizum­ab, which promis­es to remap the land­scape for the mul­ti­ple scle­ro­sis drug mar­ket.

Ocre­lizum­ab — which will now be sold as Ocre­vus — could be used to treat most MS pa­tients, a com­bi­na­tion of re­laps­ing/re­mit­ting and pri­ma­ry pro­gres­sive pa­tients. That’s a unique dis­tinc­tion that is like­ly to make this a key fo­cus among doc­tors who spe­cial­ize in treat­ing MS. And that could be a game change for every­one in the field.

Roche priced this drug for mar­ket pen­e­tra­tion at $65,000 a year, a 25% dis­count to Rebif.

“Ac­cord­ing to the NMSS, MS med­i­cines on av­er­age cost al­most 4 times more to­day than they did 12 years ago,” notes a spokesper­son for Roche. “In fact, Rebif – the 14 year-old stan­dard of care that OCRE­VUS was shown to be clin­i­cal­ly su­pe­ri­or in two RMS tri­als – now costs about $86,000. We feel that the in­dus­try needs to start to re­verse this trend, and be­lieve that pric­ing Ocre­vus 25% less than the com­para­tor in our tri­als is an im­por­tant first step.”

Eval­u­atePhar­ma has pegged con­sen­sus fore­casts of rev­enue for 2022 at $4 bil­lion for this ther­a­py, about a bil­lion dol­lars be­hind where Dupix­ent is ex­pect­ed to land. Its pres­ence in the pipeline, com­bined with a re­cent ap­proval of its check­point Tecen­triq and a few oth­er top prospects, has al­lowed Roche CEO Sev­erin Schwan to large­ly stay out of an M&A mar­ket he has long viewed as over­priced and way too risky.

In­ves­ti­ga­tors say they were able to de­ter­mine the drug in­creased the pro­por­tion of re­laps­ing/re­mit­ting MS pa­tients see­ing the elim­i­na­tion of dis­ease ac­tiv­i­ty by 75% over 96 weeks com­pared to Rebif. Most achieved that sta­tus at the end of 24 weeks of treat­ment with the ther­a­py. And the com­pa­ny al­so out­lined new pos­i­tive da­ta on the elim­i­na­tion of dis­ease pro­gres­sion among pri­ma­ry pro­gres­sive MS pa­tients com­pared to a place­bo.

Bri­an Sko­r­ney, Baird an­a­lyst

The da­ta paves the way for a new con­tender that is en­ter­ing a fast-chang­ing and fu­ri­ous­ly com­pet­i­tive mar­ket. A 40mg gener­ic ver­sion of Te­va’s Co­pax­one may be on the way soon as Bio­gen’s flag­ship drug Tec­fidera con­tin­ues to see its mar­ket de­te­ri­o­rate. That ero­sion has left Bio­gen in­cred­i­bly vul­ner­a­ble to grow­ing crit­i­cism of its busi­ness mod­el.

“Re­call, we’ve ad­vo­cat­ed that Tysabri should be an ob­vi­ous tar­get for Ocre­vus in RMS giv­en the as­so­ci­at­ed safe­ty risks, sim­i­lar­i­ties in ad­min­is­tra­tion, etc,” not­ed Baird’s Bri­an Sko­r­ney. “Docs in­di­cat­ed that about 50% of Ocre­vus pa­tients would like­ly be PPMS pa­tients, with 11% com­ing from Tysabri and an­oth­er 11% switch­es from Tec­fidera. This im­plies an al­most 20% hit to over­all Tysabri de­mand. How­ev­er, when asked about long-term trends, gener­ic 40mg Co­pax­one, and oth­er com­pet­i­tive threats, docs still be­lieve Tec­fidera could see a 20%+ de­cline in scripts by YE18.”

San­dra Horn­ing

“The FDA’s ap­proval of OCRE­VUS is the be­gin­ning of a new era for the MS com­mu­ni­ty and rep­re­sents a sig­nif­i­cant sci­en­tif­ic ad­vance with this first-in-class B cell tar­get­ed ther­a­py,” said San­dra Horn­ing, chief med­ical of­fi­cer and head of Glob­al Prod­uct De­vel­op­ment. “Un­til now, no FDA-ap­proved treat­ment has been avail­able to the pri­ma­ry pro­gres­sive MS com­mu­ni­ty, and some peo­ple with re­laps­ing forms of MS con­tin­ue to ex­pe­ri­ence dis­ease ac­tiv­i­ty and dis­abil­i­ty pro­gres­sion de­spite avail­able ther­a­pies. We be­lieve OCRE­VUS, giv­en every six months, has the po­ten­tial to change the dis­ease course for peo­ple with MS, and we are com­mit­ted to help­ing those who can ben­e­fit gain ac­cess to our med­i­cine.”

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Federal Trade Commission commissioner Rohit Chopra testifies on Capitol Hill (AP Photo/Susan Walsh)

FTC clears Bris­tol-My­ers’ $74B deal to buy Cel­gene — but Dems sig­nal a po­ten­tial hard shift against Big Phar­ma M&A

Bristol-Myers Squibb’s record $74 billion takeover of Celgene is a done deal. And it will all be over — except for the lingering complaints from die-hard Celgene investors — on Wednesday.

Like much else that’s going on in Washington these days, the vote among the 5 FTC commissioners split along party lines, with the 3 Republicans voting to clear the way and the 2 Democrats steamed over what they see as a major M&A move that will lessen competition and innovation. And that split has big implications for the M&A side of the business if the Dems take the White House in 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

BeiGene CEO John Oyler at an Endpoints event in Shanghai, October 2018 (Credit: Endpoints News/PharmCube)

UP­DAT­ED: In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

Weeks after Amgen took a $2.7 billion stake in BeiGene, the Beijing-based biotech has secured its first-ever FDA approval for zanubrutinib, a BTK inhibitor, months ahead of schedule.

BeiGene’s drug, branded as Brukinsa, has secured accelerated approval for adult patients with mantle cell lymphoma (MCL) — a typically aggressive, rare, form of blood cancer — who have received at least one prior therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

First comes the $62 billion buyout. Then comes the asset auction and reorganization to pay down debt. Now comes the detailed pledge of a bigger, brighter future in drug development.

That’s where Takeda finds itself on R&D day today, about 11 months after closing on their Shire acquisition. R&D chief Andy Plump is joining CEO Christophe Weber and other top members of the team to outline a new set of priorities in the greatly expanded pipeline at Takeda, which has jumped into the top ranks of the world’s pharma giants in the wake of the Shire deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.

Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.